Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Hypertension

Eligibility:

All Genders

19+ years

Phase:

PHASE4

Brief Summary

Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Ability to provide written informed consent in accordance with Good Clinical Practice (GCP) and local legislation.
  • Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥95 mmHg and ≤109 mmHg, measured by manual cuff sphygmomanometer at Visit 2.
  • Age 18 years or older (or 19 years if dictated by local State/Province policies).
  • Ability to stop any current antihypertensive therapy without risk to the patient (investigator's discretion).
  • 24-hour mean DBP of ≥85 mmHg at Visit 3 as measured by Ambulatory Blood Pressure Monitoring (ABPM).
  • Exclusion criteria:
  • Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent) who:
  • were not surgically sterile; or
  • were nursing, or
  • were of childbearing potential and were NOT practicing acceptable methods of birth control, or did NOT plan to continue practicing an acceptable method throughout the study. Acceptable methods of birth control included IUD, oral, implantable or injectable contraceptives. No exceptions were made.
  • Night shift workers who routinely slept during the daytime and whose work hours included midnight to 4:00 a.m.
  • Mean seated SBP ≥180 mmHg or mean seated DBP ≥110 mmHg during any visit of the placebo run-in period.
  • Known or suspected secondary hypertension (e.g., phaeochromocytoma).
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
  • Serum Glutamate-Oxaloacetate-Transaminase (Aspartate Aminotransferase) (SGOT (AST)) or Serum Glutamate-Pyruvate-Transaminase (Alanine Aminotransferase) (SGPT (ALT)) \>2 times the upper limit of normal range, or
  • Serum creatinine \>2.3 mg/dL (or \>203 μmol/l).
  • Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney.
  • Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia.
  • Uncorrected volume depletion.
  • Further exclusion criteria apply

Exclusion

    Key Trial Info

    Start Date :

    October 9 2002

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    812 Patients enrolled

    Trial Details

    Trial ID

    NCT00274599

    Start Date

    October 9 2002

    Last Update

    December 6 2023

    Active Locations (74)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 19 (74 locations)

    1

    Boehringer Ingelheim Investigational Site

    Birmingham, Alabama, United States

    2

    Boehringer Ingelheim Investigational Site

    Phoenix, Arizona, United States

    3

    Boehringer Ingelheim Investigational Site

    Tucson, Arizona, United States

    4

    Harold B. Betton, M.D.

    Little Rock, Arkansas, United States